pyrazines has been researched along with Atherosclerosis in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 14 (82.35) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Du, M; Feng, X; Li, S; Liu, P; Wang, J; Wang, Y | 1 |
| Lei, SY; Liu, Y; Ma, LQ; Mao, T; Qiao, Y; Sun, XL; Zhang, JC; Zheng, QX | 1 |
| Dai, D; Dai, Y; Ding, Z; Mehta, JL; Wang, X | 1 |
| Guan, M; He, F; Li, C; Li, J; Wang, L; Xu, W; Xue, Y; Zeng, Y; Zheng, Z | 1 |
| Bando, YK; Ishizu, T; Kodama, K; Murohara, T; Node, K; Oyama, J; Sato, Y | 1 |
| Jin, D; Sakonjo, H; Takai, S | 1 |
| Chen, F; Fu, R; Guo, Y; Xu, Y; Zhang, Y | 1 |
| Guo, M; Liu, Y; Shi, D | 1 |
| Bult, H; De Meyer, GR; Herman, AG; Martinet, W; Van Herck, JL; Vrints, CJ | 1 |
| Bhasin, S; Guo, W; Hamilton, JA; Hruz, PW; Hua, N; Jasuja, R; Jiang, L; Miller, A; Pudney, J; Wong, S | 1 |
| Chen, S; Jiang, F; Liu, C; Qian, J; Zhang, W | 1 |
| Arias, A; Baumann, G; Dreger, H; Fechner, M; Hewing, B; Ludwig, A; Meiners, S; Stangl, K; Stangl, V; Wilck, N | 1 |
| Jiang, S; Jin, F; Li, K; Ma, S; Yang, D; Yang, Y; Zhang, X; Zhang, Y | 1 |
| Ikeda, T; Kirinoki-Ichikawa, S; Kubota, Y; Miyamoto, M; Mizuno, K; Takagi, G; Tanaka, K | 1 |
| Chen, DM; Shi, CG; Sun, MZ; Wang, GF; Wang, HF; Wang, L; Wu, SX; Xu, ZQ | 1 |
| Barbieri, M; Boccardi, V; Esposito, A; Marfella, R; Pansini, A; Paolisso, G; Rizzo, MR | 1 |
| Lu, J; Qu, ZL; Ren, XY; Ruan, QR; Zhu, DH; Zhu, M | 1 |
2 review(s) available for pyrazines and Atherosclerosis
| Article | Year |
|---|---|
The role and mechanism of tetramethylpyrazine for atherosclerosis in animal models: A systematic review and meta-analysis.
Topics: Animals; Aortic Diseases; Atherosclerosis; Disease Models, Animal; Humans; Pyrazines | 2022 |
Cardiovascular Actions and Therapeutic Potential of Tetramethylpyrazine (Active Component Isolated from Rhizoma Chuanxiong): Roles and Mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; Calcium; China; Humans; Pinellia; Pyrazines; Reperfusion Injury; Rhizome | 2016 |
3 trial(s) available for pyrazines and Atherosclerosis
| Article | Year |
|---|---|
Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study.
Topics: Adult; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Prospective Studies; Pyrazines; Research Design; Sitagliptin Phosphate; Triazoles | 2014 |
The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes.
Topics: Adiponectin; Aged; Aged, 80 and over; Atherosclerosis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Nitroglycerin; Prospective Studies; Pyrazines; Regression Analysis; Sitagliptin Phosphate; Triazoles; Vasodilation; Vasodilator Agents | 2012 |
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.
Topics: Adamantane; Atherosclerosis; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cytokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Inflammation; Nitriles; Oxidative Stress; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Tyrosine; Vildagliptin | 2013 |
12 other study(ies) available for pyrazines and Atherosclerosis
| Article | Year |
|---|---|
[Intervention effects and mechanism of Chinese herbal medicine of supplementing Qi and activating blood circulation on chronic intermittent hypoxia composite insulin resistance ApoE~(-/-) mice model].
Topics: Animals; Atherosclerosis; Blood Circulation; Drugs, Chinese Herbal; Ginsenosides; Hypoxia; Insulin Resistance; Mice; Mice, Knockout, ApoE; Pyrazines; Qi; Random Allocation | 2019 |
DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway.
Topics: Atherosclerosis; Cell Line; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Foam Cells; Humans; Lipoproteins, LDL; Macrophages; Protein Kinase C; Pyrazines; Receptors, Scavenger; Sitagliptin Phosphate; Triazoles | 2014 |
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
Topics: AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Atherosclerosis; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Pyrazines; Random Allocation; Sitagliptin Phosphate; Triazoles | 2014 |
Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
Topics: Animals; Atherosclerosis; Blood Glucose; Carotid Arteries; Chemokine CCL2; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; In Vitro Techniques; Insulin; Linagliptin; Malondialdehyde; NADPH Oxidases; Purines; Pyrazines; Quinazolines; Rats, Zucker; Sitagliptin Phosphate; Triazoles; Vasodilation | 2014 |
Digital gene expression analysis of the pathogenesis and therapeutic mechanisms of ligustrazine and puerarin in rat atherosclerosis.
Topics: Animals; Atherosclerosis; Gene Expression; Gene Ontology; Isoflavones; Male; Metabolic Networks and Pathways; Oxidative Phosphorylation; Peroxisome Proliferator-Activated Receptors; Pyrazines; Rats; Rats, Wistar | 2014 |
Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice.
Topics: Animals; Apolipoproteins E; Apoptosis; Atherosclerosis; Boronic Acids; Bortezomib; Cells, Cultured; Female; Macrophages; Mice; Mice, Knockout; Myocytes, Smooth Muscle; Phenotype; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rabbits; Rupture, Spontaneous | 2010 |
Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.
Topics: Adipose Tissue; Animals; Antiretroviral Therapy, Highly Active; Atherosclerosis; Glucose; HIV Protease Inhibitors; Humans; Insulin; Lipids; Lipolysis; Mice; Mice, Knockout; Models, Biological; Pyrazines; Receptors, LDL; Ritonavir | 2009 |
Ligustrazine improves atherosclerosis in rat via attenuation of oxidative stress.
Topics: Animals; Antioxidants; Aorta, Thoracic; Atherosclerosis; Cholesterol; Diet, Atherogenic; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Dyslipidemias; Ligusticum; Lipid Metabolism; Liver; Liver Function Tests; Male; Oxidative Stress; Phytotherapy; Pyrazines; Rats; Rats, Sprague-Dawley; Rhizome; Triglycerides; Vasodilator Agents | 2011 |
Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta; Aortic Diseases; Atherosclerosis; Boronic Acids; Bortezomib; Chemokine CCL2; Cholesterol; Computational Biology; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Inflammation Mediators; Injections, Intraperitoneal; Interleukin-6; Lipid Peroxidation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, LDL; Superoxides; Time Factors; Vascular Cell Adhesion Molecule-1; Vasodilation; Vasodilator Agents | 2012 |
Acipimox attenuates atherosclerosis and enhances plaque stability in ApoE-deficient mice fed a palmitate-rich diet.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Diet, Atherogenic; Hypolipidemic Agents; Male; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Mice; Mice, Mutant Strains; Palmitates; Plaque, Atherosclerotic; Pyrazines; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2012 |
Tetramethylpyrazine attenuates atherosclerosis development and protects endothelial cells from ox-LDL.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Cell Adhesion; Cell Culture Techniques; Cell Movement; Cells, Cultured; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Endothelial Cells; Immunohistochemistry; Ligusticum; Lipoproteins, LDL; Male; Plaque, Atherosclerotic; Pyrazines; Rabbits; Rats; Rats, Sprague-Dawley; Triglycerides | 2013 |
Tetramethylpyrazine inhibits agiontensin II-induced nuclear factor-kappaB activation and bone morphogenetic protein-2 downregulation in rat vascular smooth muscle cells.
Topics: Angiotensin II; Animals; Atherosclerosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Immunohistochemistry; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-kappa B; Pyrazines; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta | 2007 |